Journal of Dermatological Treatment

BeautyHealth 2023 Skintuition Report: The Skin Health Trends and Data Shaping the Year

Retrieved on: 
Tuesday, December 12, 2023
Cosmetics, Retail, Journal of Cosmetic Dermatology, Human, SKIN, Behavior, Treatment, Journal of Dermatological Treatment, Communication, Journal, Hydradermabrasion, Skin, Radical, Intelligence, Medicalization, Knowledge, Beauty, Face, Pharmaceutical industry, Beauty salon, Peptide, MD

This collective intelligence and proprietary data put BeautyHealth in a unique position to reflect on the trends that shaped 2023 and those that it believes will emerge in 2024.

Key Points: 
  • This collective intelligence and proprietary data put BeautyHealth in a unique position to reflect on the trends that shaped 2023 and those that it believes will emerge in 2024.
  • “We are thrilled to unveil our first-ever Skintuition Report and share insights culled from our connected platform and global community of skin health providers.
  • In addition to consumer and provider behavior data, the 2023 BeautyHealth Skintuition Report catalogues long-standing and more recent peer-reviewed clinical studies, which analyze the efficacy of the Hydrafacial treatment.
  • Data insights in the Skintuition Report are generated from BeautyHealth sales data, Hydrafacial Syndeo device data, published clinical studies, provider testimonials, and third-party measurement tools.

Dermavant Launches First Commercial for VTAMA® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque Psoriasis

Retrieved on: 
Tuesday, November 22, 2022
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Itch, Inflammatory bowel disease, Marketing, Cell, Groin, Neck, Irritation, Multimedia, Headache, Body surface area, Empathy, Face, Journal of Dermatological Treatment, Risk, Human, Aryl hydrocarbon receptor, Itchy, Folliculitis, Obesity, Research, Depression, Progress, Pain, Hypertension, Smoking, NPA, Incidence, Stinger, FDA, Psoriasis, Common, Atopic dermatitis, National Psoriasis Foundation, Swelling, Rash, Genetics, Roivant Sciences, Therapy, Diabetes, Dermatology, Food, Veni, vidi, vici, Calendar, Skin, Injection, Nose, Prescription, Weather, Inflammation, Gesellschaft mit beschränkter Haftung, Patient, Pharmaceutical industry, Cosmetics, Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology

Many have been waiting a long time for a different plaque psoriasis treatment like VTAMA cream.

Key Points: 
  • Many have been waiting a long time for a different plaque psoriasis treatment like VTAMA cream.
  • The commercial gives topical plaque psoriasis patients aka the silent majority a voice, empowering them to demand more from their topical plaque psoriasis treatment and truly feel heard.
  • Indication: VTAMA (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
  • Plaque psoriasis, also called psoriasis vulgaris, is the most common form and affects about 80 to 90% of people with psoriasis.

Serendia, LLC Files Patent Infringement Lawsuits against Cartessa and SHEnB Relating to Radio Frequency Microneedling Devices

Retrieved on: 
Wednesday, September 22, 2021
Dermis, Invention, Rosacea, SRF, Method, Douglas v. U.S. District Court ex rel Talk America, Apparatus, Sale, Tempo, Continuous wave, FDA, Patient, Epidermis, Journal of Dermatological Treatment, Pigment, LLC, District court, Pain, Skin care, Burn, Dermatology, RF, Kim Sung-hwan (footballer), AMP, Skin, Medical imaging, Pharmaceutical industry

The lawsuits assert that the accused produce, import and sell infringing products and services throughout the U.S.

Key Points: 
  • The lawsuits assert that the accused produce, import and sell infringing products and services throughout the U.S.
  • The infringing products include Vivace and Virtue RF, which are radio frequency ("RF") microneedling devices manufactured and/or distributed by the accused for treatment of dermatological issues.
  • Sylfirm X is the world's first and only FDA cleared Pulsed Wave and Continuous Wave RF microneedling device.
  • The lawsuits accuse infringement of four U.S. patents: 9,320,536 (titled "Method, System, and Apparatus for Dermatological Treatment.